Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4319fe3d827bd24add491d4ed90e7692 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16671 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16621 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
filingDate |
2016-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df6d67b59740b83304b8e93f493ab2c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66e33f7907b9faa8ec9a272e25a61e01 |
publicationDate |
2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10806761-B2 |
titleOfInvention |
Oncolytic HSV1 vector and methods of use |
abstract |
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a second generation oncolytic virus rQNestin34.5v2 with less toxicity that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic virus described herein is suitable for treatment of glioblastoma, as well as other cancers. |
priorityDate |
2015-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |